Agitation in Alzheimer's Disease
What is agitation in Alzheimer's Disease (AAD)?
Agitation is a common behavioral symptom experienced by a majority of patients with Alzheimer's Disease,
Agitation in Alzheimer's Disease (AAD) which includes emotional lability, restlessness, irritability, and aggression,1 is one of the most distressing and debilitating of the behavioral complications of Alzheimer's disease. Both sleep disturbances and agitation are common and co-morbid features of Alzheimer's disease.1,2,3
AAD has significant negative consequences for patients as well as their caregivers. Agitation is one of the most common reasons for Alzheimer's disease patients having to transition to nursing homes and other long-term care settings.
https://www.tonixpharma.com/therapeutic-areas/aad
Recent BIIB News
- Nike Stock Drops 14% in Pre-Market; Nokia Acquires Infinera for $2.3 Billion, and More News • IH Market News • 06/28/2024 10:50:25 AM
- The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 06/28/2024 09:45:00 AM
- “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China • GlobeNewswire Inc. • 06/27/2024 11:39:36 PM
- Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm • PR Newswire (US) • 06/25/2024 09:45:00 AM
- Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB • PR Newswire (US) • 06/20/2024 09:45:00 AM
- Shareholders of Biogen Inc. Should Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB • PR Newswire (US) • 06/17/2024 09:45:00 AM
- Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 06/10/2024 09:45:00 AM
- FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease • GlobeNewswire Inc. • 06/09/2024 11:37:43 PM
- FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease • PR Newswire (US) • 06/09/2024 11:30:00 PM
- Investors who lost money on Biogen Inc. (BIIB) should contact The Gross Law Firm about pending Class Action - BIIB • PR Newswire (US) • 06/05/2024 09:45:00 AM
- Economic Worries May Lead To Weakness On Wall Street • IH Market News • 06/04/2024 01:10:54 PM
- Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel • GlobeNewswire Inc. • 06/03/2024 11:30:00 AM
- Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS • GlobeNewswire Inc. • 05/30/2024 08:51:04 PM
- OpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More News • IH Market News • 05/23/2024 11:40:51 AM
- Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis • GlobeNewswire Inc. • 05/16/2024 11:30:14 AM
- Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis • PR Newswire (US) • 05/16/2024 11:30:00 AM
- Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status • GlobeNewswire Inc. • 05/14/2024 11:33:37 PM
- Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status • PR Newswire (US) • 05/14/2024 11:30:00 PM
- Biogen Reports Progress on Corporate Responsibility Priorities • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA • PR Newswire (US) • 03/31/2024 11:30:00 PM
- New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy • GlobeNewswire Inc. • 03/06/2024 12:30:51 PM
- Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting • GlobeNewswire Inc. • 03/04/2024 09:15:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 12:54:07 AM
- Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP • GlobeNewswire Inc. • 02/23/2024 12:00:26 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM